BNTX - Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor
2024-05-23 10:15:42 ET
Summary
- Moderna's stock price is rising on fears of a new infectious disease outbreak, and this is reminiscent of the company's pandemic gains.
- Moderna and Pfizer have been in talks with the Department of Health and Human Services after a second case of avian flu infection was reported this week.
- Other vaccine stocks, including CureVac, BioNTech, and Pfizer, have also seen share price gains in response to the perceived threat.
- The HHS may wish to stockpile vaccine products against H5N1 bird flu, and an announcement is expected to clarify any role that Moderna and Pfizer may play.
- MRNA stock price buoyancy is hardly justified on fears of another pandemic. However, markets being markets, I'd expect to see further price volatility, and potentially a small revenue opportunity for Moderna.